Clinical Trials
151 trialsGraft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
ICLL07GAI
French Innovative Leukemia Organisation
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Cancer Trials Ireland
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Institutes of Health Clinical Center (CC)
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
M.D. Anderson Cancer Center
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Intra-Osseous Co-Transplant of UCB and hMSC
Case Comprehensive Cancer Center
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Masonic Cancer Center, University of Minnesota
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center